Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension
Status:
Recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
This is an open-label extension study for patients previously enrolled in the AB2 Bio Ltd.
ongoing Phase III clinical trial NLRC4/XIAP.2016.001 (IND N° 127953). This OLE study will
evaluate the long-term safety and tolerability of Tadekinig alfa in patients suffering from
pediatric monogenic autoinflammatory diseases harboring deleterious mutations of NLRC4 and
XIAP.